70 related articles for article (PubMed ID: 2546286)
1. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.
Kambayashi J; Watase M; Kawasaki T; Shiba E; Sakon M; Mori T; Isaka Y; Kimura K; Kamada T
Adv Second Messenger Phosphoprotein Res; 1992; 25():383-93. PubMed ID: 1313269
[No Abstract] [Full Text] [Related]
4. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
Ashida S; Sakuma K
Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
[No Abstract] [Full Text] [Related]
5. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
6. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
7. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin E1 and prostacyclin in four platelet "function" tests.
O'Brien JR; Etherington MD; Salmon GP
Thromb Res; 1988 Apr; 50(1):237-41. PubMed ID: 2840751
[No Abstract] [Full Text] [Related]
8. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Tanaka NG; Tohgo A; Ogawa H; Osada Y
Anticancer Res; 1986; 6(4):543-8. PubMed ID: 3019218
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
Tohgo A; Tanaka NG; Osada Y
Invasion Metastasis; 1990; 10(1):1-17. PubMed ID: 2154413
[TBL] [Abstract][Full Text] [Related]
10. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
11. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
Sills T; Heptinstall S
Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
[TBL] [Abstract][Full Text] [Related]
12. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.
Rickards KJ; Andrews MJ; Waterworth TH; Alexander GB; Cunningham FM
J Vet Pharmacol Ther; 2003 Aug; 26(4):277-82. PubMed ID: 12887610
[TBL] [Abstract][Full Text] [Related]
15. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
16. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
18. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.
Cauwenberghs N; Schlammadinger A; Vauterin S; Cooper S; Descheemaeker G; Tornai I; Deckmyn H
Thromb Haemost; 2001 Apr; 85(4):679-85. PubMed ID: 11341505
[TBL] [Abstract][Full Text] [Related]
19. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib.
Fujimura Y; Ikeda Y; Miura S; Yoshida E; Shima H; Nishida S; Suzuki M; Titani K; Taniuchi Y; Kawasaki T
Thromb Haemost; 1995 Aug; 74(2):743-50. PubMed ID: 8585016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
